Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for VALCYTE
- Nanatinostat Plus Valganciclovir in Patients With Advanced EBV+ Solid Tumors, and in Combination With Pembrolizumab in EBV+ RM-NPC
- A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma Patients
- Clinical Trial of Efficacy and Safety of the Combination of Reduced Duration Prophylaxis Followed by Immuno-guided Prophylaxis in Lung Transplant Recipients.
- Pharmacokinetic Parameters of Innovative Valganciclovir Versus Generic Valganciclovir
- Valganciclovir Four Weeks Prior to cART Initiation Compared to Standard Therapy for Disseminated Kaposi Sarcoma
- Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants
- The Strategy in the Prevention of Renal Post-transplant Cytomegalovirus Infection Among Chinese Population
- A Pilot Trial of Herpesvirus Treatment in Idiopathic Pulmonary Fibrosis (IPF)
- Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma
- Valganciclovir Dosing in Pediatric Solid Organ Transplant Recipients
- Bioavailability Study of Valganciclovir Hydrochloride Tablets 450 mg Under Fasting Condition
- Bioavailability Study of Valganciclovir Hydrochloride Tablets 450 mg Under Fed Condition
- Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation
- Congenital Cytomegalovirus: Efficacy of Antiviral Treatment
- ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation
- Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Randomized Controlled Trial
- Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection
- Tocilizumab for KSHV-Associated Multicentric Castleman Disease
- A Study of Oral Valcyte (Valganciclovir) in Pediatric Kidney Transplant Recipients
- Antiviral Treatment of Chronic Lymphocytic Leukemia
- Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
- Study Comparing Valganciclovir Versus Ganciclovir in Patients Following Allogeneic Stem Cell Transplantation
- A Study on the Pharmacokinetics and Safety of Valcyte (Valganciclovir) in Pediatric Heart Transplant Recipients Less Than 4 Months of Age
- Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
- Certican® (Everolimus) Against Cytomegalovirus Disease in Renal Transplant Patients
- Valganciclovir for Treatment of Cytomegalovirus Infection in Solid Organ Transplant Patients
- Oral Valganciclovir Versus Valacyclovir
- CFAR Study in Patients With Chronic Lymphocytic Leukemia
- Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV)
- VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients
- Efficacy and Safety of Valcyte® as an add-on Therapy in Patients With Malignant Glioblastoma and Cytomegalovirus (CMV) Infection
- A Relative Bioavailability Study of Valcyte (Valganciclovir) in Lung Transplant Recipients With or Without Cystic Fibrosis.
- A Study of Valcyte (Valganciclovir) CMV Prophylaxis After Renal Transplantation
- Valganciclovir to Treat HHV-8 Associated Multicentric Castleman's Disease
- IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
- WP16302 A Bioequivalence Study Comparing Ganciclovir From the Valganciclovir Syrup Formulation and the Commercial Valganciclovir 450mg Tablet (Valcyte®) at a Dose of 900mg in Kidney Transplant Recipients
- Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation
- Suppression of Oral HHV8 Shedding With Valganciclovir
- Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity
- A Study of Valcyte (Valganciclovir) Syrup Formulation in Pediatric Solid Organ Transplant Recipients
Clinical trials list
click for details